Selected article for: "expression analysis and RNA expression analysis"
Author: Nikitopoulou, Ioanna; Fanidis, Dionysios; Ntatsoulis, Konstantinos; Moulos, Panagiotis; Mpekoulis, George; Evangelidou, Maria; Vassiliou, Alice G.; Dimakopoulou, Vasiliki; Jahaj, Edison; Tsipilis, Stamatios; Orfanos, Stylianos E.; Dimopoulou, Ioanna; Angelakis, Emmanouil; Akinosoglou, Karolina; Vassilaki, Niki; Tzouvelekis, Argyrios; Kotanidou, Anastasia; Aidinis, Vassilis
Title: Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells
  • Cord-id: 1zovqdn2
  • Document date: 2021_9_16
    • ID: 1zovqdn2
    Snippet: Autotaxin (ATX; ENPP2) is a secreted lysophospholipase D catalyzing the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling phospholipid. Genetic and pharmacologic studies have previously established a pathologic role for ATX and LPA signaling in pulmonary injury, inflammation, and fibrosis. Here, increased ENPP2 mRNA levels were detected in immune cells from nasopharyngeal swab samples of COVID-19 patients, and increased ATX serum levels were found in severe COVID-1
    Document: Autotaxin (ATX; ENPP2) is a secreted lysophospholipase D catalyzing the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling phospholipid. Genetic and pharmacologic studies have previously established a pathologic role for ATX and LPA signaling in pulmonary injury, inflammation, and fibrosis. Here, increased ENPP2 mRNA levels were detected in immune cells from nasopharyngeal swab samples of COVID-19 patients, and increased ATX serum levels were found in severe COVID-19 patients. ATX serum levels correlated with the corresponding increased serum levels of IL-6 and endothelial damage biomarkers, suggesting an interplay of the ATX/LPA axis with hyperinflammation and the associated vascular dysfunction in COVID-19. Accordingly, dexamethasone (Dex) treatment of mechanically ventilated patients reduced ATX levels, as shown in two independent cohorts, indicating that the therapeutic benefits of Dex include the suppression of ATX. Moreover, large scale analysis of multiple single cell RNA sequencing datasets revealed the expression landscape of ENPP2 in COVID-19 and further suggested a role for ATX in the homeostasis of dendritic cells, which exhibit both numerical and functional deficits in COVID-19. Therefore, ATX has likely a multifunctional role in COVID-19 pathogenesis, suggesting that its pharmacological targeting might represent an additional therapeutic option, both during and after hospitalization.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and admission prior: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and liver steatosis: 1
    • acute ards respiratory distress syndrome and local production: 1, 2
    • acute ards respiratory distress syndrome and long term follow: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and lopinavir ritonavir chloroquine: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and lpa lysophosphatidic acid: 1, 2
    • acute ards respiratory distress syndrome and lpa lysophosphatidic acid extracellular production: 1, 2
    • acute ards respiratory distress syndrome and lpa lysophosphatidic acid extracellular production responsible: 1, 2
    • acute ards respiratory distress syndrome and lpa production: 1, 2
    • acute ards respiratory distress syndrome and lpa receptor: 1
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75